These results indicate that BsADC 3 can maintain high cytotoxic activity against tumor cells with dual high expression while reducing the cytotoxic activity against cells with moderate EpCAM expression, thereby helping to expand the therapeutic window in the clinic. Here, EPCAM is linked to neoplasm.